Abstract
Stage IV melanoma exhibits a diverse range of tumor biology from indolent to aggressive disease. Many important prognostic factors have already been identified. Despite this, the behavior of metastatic melanoma remains difficult to predict. We sought to determine if any primary tumor characteristics affect survival following the diagnosis of stage IV melanoma. All patients diagnosed with stage IV melanoma between January 2003 and December 2012 were identified from the Victorian Melanoma Service database. Retrospective chart review was performed to collect data on primary tumor characteristics (thickness, ulceration, mitotic rate, melanoma subtype, or occult primary). Known and suspected prognostic factors were additionally collected (time to diagnosis of stage IV disease, age, sex, stage, receipt of chemotherapy, and era of recurrence). The effect of primary tumor characteristics on overall survival from the date of diagnosis of stage IV disease was assessed. A total of 227 patients with a median follow-up of 5 years from diagnosis of stage IV disease were identified. Median overall survival of the cohort was 250 days.Of the primary tumor characteristics assessed, only tumor thickness affected survival from diagnosis of stage I...Continue Reading
References
Jun 24, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Vijuk, A S Coates
Dec 20, 2008·Clinics in Dermatology·Claus Garbe, Ulrike Leiter
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chris C LeeDonald L Morton
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongRichard F Kefford
Apr 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F ThompsonVernon K Sondak
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Nov 8, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander M M EggermontAlan Spatz
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adèle C GreenMark Smithers
Jun 28, 2012·Lancet·Axel HauschildPaul B Chapman
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Sep 30, 2014·The New England Journal of Medicine·Georgina V LongKeith Flaherty
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 4, 2015·Lancet·Georgina V LongKeith Flaherty
Citations
Nov 5, 2016·International Journal of Cancer. Journal International Du Cancer·Anna DeschStefan W Schneider
Apr 27, 2019·Melanoma Research·Melissa A WilsonIman Osman
Nov 8, 2020·Japanese Journal of Clinical Oncology·Faruk Tas, Kayhan Erturk
Feb 23, 2021·Laryngoscope Investigative Otolaryngology·Elizabeth KimSamir S Khariwala
Mar 29, 2021·Cancer Immunology, Immunotherapy : CII·Danielle VerverAstrid A M van der Veldt